EcoR1 Capital — 2017 Investments
3 investments dated 2017 · listed companies and verified rows first · show all
Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Akshay Vaishnaw(President of Research & Development and Director)R. Keith Woods(Chief Operating Officer)in
Co-investorsSamsara BioCapitalARCH Venture PartnersPolaris Partners
Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) that combine monoclonal antibody specificity with oligonucleotide precision for targeted delivery of RNA therapeutics to treat rare genetic muscle diseases.
BiotechDeep TechHealthtechMedical DevicesLa Jolla, US
Troy Wilson PhD., JD(Executive Officer, Director)P. Kent Hawryluk(Executive Officer)inMark E. Davis(Director)Troy Wilson(Executive Officer, Director)in
BoardTodd Brady(Director)Michael Martin PhD.(Director)
Co-investorsAvoro Capital AdvisorsBrace PharmaF-Prime CapitalFrazier Life SciencesMoore Venture Partners
Kezar Life Sciences is a clinical-stage biotechnology company developing small-molecule therapeutics for immune-mediated diseases and cancer.
BiotechSouth San Francisco, US
John F. Fowler(Executive Officer, Director)inChristopher J. Kirk(Executive Officer, Director)
BoardDr. Gerald Chan(Director)Dr. Jean-Pierre Sommadossi(Director)
Co-investorsBay City CapitalChiesi VenturesPappas CapitalQiming Venture Partners USASolasta VenturesCowen Healthcare Investments+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.









